Last reviewed · How we verify
Cyclocort (AMCINONIDE)
Cyclocort (AMCINONIDE) is a corticosteroid medication developed by Astellas, targeting the glucocorticoid receptor. It is a small molecule drug approved by the FDA in 1979 for various skin conditions, including atopic dermatitis, contact dermatitis, and plaque psoriasis. Cyclocort is off-patent, with multiple generic manufacturers available. As a corticosteroid, it works by reducing inflammation and suppressing the immune system. Key safety considerations include potential skin thinning and increased risk of infections.
At a glance
| Generic name | AMCINONIDE |
|---|---|
| Sponsor | Astellas Pharma |
| Drug class | Corticosteroid [EPC] |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1979 |
Approved indications
- Atopic dermatitis
- Contact dermatitis
- Discoid lupus erythematosus
- Eruption of skin
- Granuloma annulare
- Lichen simplex chronicus
- Plaque psoriasis
- Primary cutaneous T-cell lymphoma
- Pruritus ani
- Pruritus of genital organs
- Scalp psoriasis
- Seborrheic dermatitis
Common side effects
- skin atrophy
- miliaria
- striations
- secondary infection
- maceration of the skin
- allergic contact dermatitis
- perioral dermatitis
- hypopigmentation
- hypertrichosis
- acneiform eruptions
- folliculitis
- dryness
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclocort CI brief — competitive landscape report
- Cyclocort updates RSS · CI watch RSS
- Astellas Pharma portfolio CI